J&J strikes deal with Emergent BioSolutions on coronavirus vaccine manufacturing

[NEW JERSEY] Johnson & Johnson said on Thursday it had struck a deal with Emergent BioSolutions to use its manufacturing facilities in an effort to make more than 1 billion doses of a vaccine it is testing to stop the novel coronavirus.

The US healthcare conglomerate said the deal was the first in a series of prospective global partnerships to accelerate manufacturing of its experimental Covid-19 vaccine candidate, even before it has a signal that it works.

J&J plans to start human testing by September, with an eye on having it ready under an emergency use authorisation in early 2021, far quicker than the typical 18-month period that it takes for vaccines to be tested, approved and then manufactured.

Under the deal, valued at about US$135 million (S$192.6 million), Emergent said it would provide drug substance manufacturing services and was reserving large-scale manufacturing capacity.

J&J and the US government are investing US$1 billion to create enough manufacturing capacity for the experimental vaccine candidate to stop the virus that has killed nearly 185,000 people around the globe.

REUTERS

GET BT IN YOUR INBOX DAILY

Start and end each day with the latest news stories and analyses delivered straight to your inbox.

Sign UpVIEW ALL